KNKento Nakajima

Kento Nakajima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kento Nakajima has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Ichiro Takeuchi

    Advanced Critical Care and Emergency Center, Yokohama City University Medical Center, Yokohama, JPN

    6 shared publications
  • Takeru Abe

    Center for Integrated Sciences and Humanities Fukushima Medical University Fukushima Japan

    4 shared publications
  • Hayato Taniguchi

    Department of Emergency Medicine, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan

    3 shared publications
  • Kazuya Sakai

    Yokohama City University

    3 shared publications
  • Keishi Yamaguchi

    Department of Emergency Medicine, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan

    3 shared publications
  • Tomoki Doi

    Department of Emergency Medicine, Yokosuka Kyosai Hospital, Yokosuka, JPN

    3 shared publications

Latest Publications

  • Open Access

    Hemostatic Achievement After Introduction of Venovenous Extracorporeal Membrane Oxygenation for Severe Multiple Trauma: A Case Study

    by Takahiro Michishita, Kento Nakajima, Tomoki Doi, Kurumi Mori, Ichiro Takeuchi

    Venovenous extracorporeal membrane oxygenation (VV-ECMO) is indicated for patients with severe respiratory failure who cannot be managed with a ventilator. We report a case of severe chest trauma with an injury severity score of 66, in which hemostasis was achieved after VV-ECMO. A 29-year-old male patient sustained a fall injury from a 4-m cliff. The fall resulted in significant traumatic cerebral hemorrhage, bilateral pulmonary contusion, hemothorax, pelvic fracture, and limb fracture. During transcatheter arterial embolization, the patient continued to bleed from the left lung and showed progressive hypoxemia. In addition, the patient was unable to maintain tidal volume and experienced hypercapnia, and thus, VV-ECMO was introduced, followed by a thoracotomy to stop the bleeding. On the third day of hospitalization, the patient was weaned off VV-ECMO, and on day 35, he was transferred to a rehabilitation hospital for recovery. VV-ECMO may serve as a “bridge” until hemostatic maneuvers for severe chest trauma are completed and may contribute to help ensure adequate respiration.


  • Open Access

    A simulation study of high-flow versus normal-flow three-way stopcock for rapid fluid administration in emergency situations: A randomised crossover design

    by Keishi Yamaguchi, Tomoki Doi, Takashi Muguruma, Kento Nakajima, Kyota Nakamura, Takeru Abe, Ichiro Takeuchi, Naoto Morimura


  • Extravasation and outcomes in computed tomography and angiography in patients with pelvic fractures requiring transcatheter arterial embolization: A single-center observational study

    by Kento Nakajima, Keishi Yamaguchi, Takeru Abe, Hayato Taniguchi, Saori Mizukami, Zenjiro Sekikawa, Ichiro Takeuchi

    BACKGROUND: Extravasation on contrast-enhanced computed tomography (CECT) is a helpful indicator of the need for transcatheter arterial embolization (TAE) for pelvic fractures. However, previous reports were inconsistent on cases in which angiography is necessary, even though there is no extravasation on computed tomography. This study aimed to describe and analyze the contradictory findings in cases where extravasation is observed on angiography but not on CECT, to contribute to improved management of patients with pelvic fractures. METHODS: This was a retrospective single-center study. Patients with pelvic fractures who underwent CECT and TAE between 2014 and 2020 were included. We classified the patients into three groups: CECT and angiography with extravasation (CT+Angio+), CECT with no extravasation and angiography with extravasation (CT−Angio+), and CECT with extravasation and angiography without extravasation (CT+Angio−). RESULTS: A total of 113 patients were included in the study: the CT+Angio+ group had 54 patients, CT−Angio+ group, 47; and CT+Angio− group, 12. The CT−Angio+ group had a significantly longer time from arrival to CECT than the CT+Angio+ group (27 minutes vs. 23 minutes, p < 0.05). The CT−Angio+ group had significantly more blood transfusions (fresh frozen plasma, platelets) within 24 hours than the CT+Angio− group did (p < 0.05), and ventilator management days (p < 0.05) and intensive care unit stays (p < 0.05) were significantly longer. CONCLUSION: There was no significant difference in outcomes among the three groups. There was no difference in severity, transfusion volume, or mortality in patients with pelvic fractures needing TAE, classified as CT−Angio+, compared with that of CT+Angio+ patients. Even in the absence of extravasation in the pelvic region on CECT, angiography or TAE may still be necessary. LEVEL OF EVIDENCE: Therapeutic/Care Management, Level IV.


  • Open Access

    Temporal change in Syndecan-1 as a therapeutic target and a biomarker for the severity classification of COVID-19

    by Fumihiro Ogawa, Yasufumi Oi, Kento Nakajima, Reo Matsumura, Tomoki Nakagawa, Takao Miyagawa, Kazuya Sakai, Ryo Saji, Hayato Taniguchi, Kohei Takahashi, et al.

    Background: Coronavirus disease 2019 (COVID-19) pneumonitis associated with severe respiratory failure is associated with high mortality. The pathogenesis of COVID-19 is associated with microembolism or microvascular endothelial injuries. Here, we report that syndecan-1 (SDC-1), a component of the endothelial glycocalyx, may be a biomarker of severity classification for COVID-19 related to endothelial injury. Methods and analysis: We analyzed the data of COVID-19 patients for 1 year from February 2020 at Yokohama City University Hospital and Yokohama City University Medical Center Hospital. We selected COVID-19 patients who required admission care, including intensive care, and analyzed the classification of severe and critical COVID-19 retrospectively, using various clinical data and laboratory data with SDC-1 by ELISA. Results: We analyzed clinical and laboratory data with SDC-1 in five severe COVID-19 and ten critical COVID-19 patients. In the two groups, their backgrounds were almost the same. In laboratory data, the LDH, CHE, and CRP levels showed significant differences in each group (P = 0.032, P < 0.0001, and P = 0.007, respectively) with no significant differences in coagulation-related factors (platelet, PT-INR, d-dimer, ISTH score; P = 0.200, 0.277, 0.655, and 0.36, respectively). For the clinical data, the SOFA score was significantly different from admission day to day 14 of admission (p < 0.0001). The SDC-1 levels of critical COVID-19 patients were significantly higher on admission day and all-time course compared with the levels of severe COVID-19 patients (P = 0.009 and P < 0.0001, respectively). Conclusions: Temporal change of SDC-1 levels closely reflect the severity of COVID-19, therefore, SDC-1 may be a therapeutic target and a biomarker for the severity classification of Covid-19.


  • Open Access

    Serum cholinesterase on admission as a predictor of COVID-19 pneumonia severity and mortality

    by Kento Nakajima, Takeru Abe, Ryo Saji, Fumihiro Ogawa, Hayato Taniguchi, Keishi Yamaguchi, Kazuya Sakai, Tomoki Nakagawa, Reo Matsumura, Yasuhumi Oi, et al.

    Background Although some predictors of COVID-19 pneumonia severity and mortality have been identified, much of the pathophysiology of this emerging infectious disease remains unclear. We hypothesized that a patient’s cholinesterase level on admission could predict COVID-19 pneumonia severity and mortality. Methods We retrospectively collected data of 26 COVID-19 pneumonia patients from February–May 2020. Outcomes were aggravation of symptoms and in-hospital mortality. We compared receiver operating curves of cholinesterase, C-reactive protein, lymphocytes, albumin, D-dimer, and PaO2/FiO2 ratio and examined prediction accuracy. Regarding the interaction between cholinesterase and other variables, each independent variable was divided into two groups using cutoff values, and interaction terms were created. Results Cholinesterase levels on admission were significantly lower in the severe group than in the mild-to-moderate group (326 vs. 218 IU/L, p = 0.006; area under the curve: 0.81; 95% confidence interval 0.61–0.94). When comparing the area under the curve, cholinesterase was comparable to C-reactive protein, albumin, lymphocytes, and PaO2/FiO2 ratio other than D-dimer in the prediction accuracy of severe cases and mortality. Cholinesterase levels on admission were significantly lower in the death group than in the survival group (274 vs. 187.5 IU/L, p = 0.028; area under the curve: 0.79; 95% interval 0.58–0.93). Regarding the interaction between cholinesterase and established predictors, the prediction accuracy of both severity and death was higher when cholinesterase was combined with each predictor than when cholinesterase was used alone. Conclusions Cholinesterase may reflect the disease state of COVID-19 pneumonia, suggesting that a patient’s cholinesterase level on admission may be useful as a predictor of severity and prognosis.

  • Open Access

    A Case of Coronavirus Disease 2019 Treated With Ciclesonide

    by Kento Nakajima, Fumihiro Ogawa, Kazuya Sakai, Munehito Uchiyama, Yutaro Oyama, Hideaki Kato, Ichiro Takeuchi


  • Open Access

    Environmental maintenance with effective and useful zoning to protect patients and medical staff from COVID‐19 infection

    by Fumihiro Ogawa, Hideaki Kato, Kazuya Sakai, Kana Nakamura, Mizuki Ogawa, Munehito Uchiyama, Kento Nakajima, Yutaro Ohyama, Takeru Abe, Ichiro Takeuchi

    Aim: The coronavirus disease 2019 (COVID‐19) pandemic has accelerated all over the world, and global health‐care systems have become overwhelmed with potentially infectious patients seeking testing and care. It is essential to set up effective and useful zoning to prevent the spread of infection to and from medical staff or other patients with effective use of standard precautions with personal protective equipment (PPE).Methods: We repurposed a general ward into an acute care unit for severe COVID‐19 patients taking into consideration airflow, the direction of movement of medical staff, and prevention of the spread of infection to medical staff and other patients. We checked the daily condition and body temperature of all medical staff for 60 days.Results: There was no evidence of COVID‐19 infection in any medical staff or other patients during the period thanks to effective and useful zoning with PPE.Conclusion: Special wards and rooms should be set up for future protection of medical staff and other patients, and prevent the explosion of COVID‐19 infection with effective and useful zoning with PPE.


  • Open Access

    Does the conventional landmark help to place the tip of REBOA catheter in the optimal position? A non-controlled comparison study

    by Kento Nakajima, Hayato Taniguchi, Takeru Abe, Keishi Yamaguchi, Tomoki Doi, Ichiro Takeuchi, Naoto Morimura

    Resuscitative endovascular balloon occlusion of the aorta (REBOA) for patients with traumatic torso hemorrhagic shock is available to keep a minimum level of circulatory status as a bridge to definitive therapy. However, the trajectory for placement of REBOA in the aorta has not yet been clearly defined. We conducted a retrospective observational cohort study in the two tertiary critical care and emergency center from December 2014 to October 2018. A total of 28 patients who underwent focused assessment with sonography for trauma (FAST) were studied via contrast computed tomography (CT), and 27 were analyzed. We divided patients into two groups based on our CT findings. The REBOA deflate group included 16 patients, and the inflate group included 11 patients. The median trace value (interquartile range) of the blood vessel center line from the common femoral artery to the tip of REBOA (blood vessel length) and the length of REBOA itself from the common femoral artery to the tip of REBOA (REBOA insertion length) were 56.2 cm (54.5–57.2) and 55.2 cm (54.2–55.6), respectively (p < 0.0001) for the deflated group, and 51.4 cm (42.1–56.6) and 50.3 cm (42.3–55.0) (p = 0.594), respectively, for the inflated group. If REBOA was deflated, it was placed 1.0 cm longer than the insertion length of REBOA catheter itself, but that was not the case when inflating REBOA. The individual difference was large to the extent that the balloon inflated and the extent to which the balloon was pushed back toward the caudal depending on the degree of blood pressure. Further studies would be needed to validate the study findings.